149 related articles for article (PubMed ID: 33863615)
21. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer.
Wang J; Kalhor N; Hu J; Wang B; Chu H; Zhang B; Guan Y; Wu Y
PLoS One; 2016; 11(10):e0163397. PubMed ID: 27695079
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer.
Zhang H; Xia H; Zhang L; Zhang B; Yue D; Wang C
Am J Surg; 2015 Sep; 210(3):526-35. PubMed ID: 26105800
[TBL] [Abstract][Full Text] [Related]
24. A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.
Liang S; Li C; Gao Z; Li J; Zhao H; Yu J; Meng X
Int Immunopharmacol; 2021 Jan; 90():107178. PubMed ID: 33218939
[TBL] [Abstract][Full Text] [Related]
25. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
26. The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy.
Wang D; Guo D; Li A; Wang P; Teng F; Yu J
Future Oncol; 2020 Mar; 16(9):439-449. PubMed ID: 32141321
[No Abstract] [Full Text] [Related]
27. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection.
Azizi M; Peyton CC; Boulware DC; Chipollini J; Juwono T; Pow-Sang JM; Spiess PE
Eur Urol Focus; 2019 Nov; 5(6):1085-1090. PubMed ID: 29937330
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil-to-lymphocyte ratio for the prediction of soft tissue sarcomas response to pre-operative radiation therapy.
Martinez C; Asso RN; Rastogi N; Freeman CR; Cury FL
Radiother Oncol; 2024 Jun; 195():110239. PubMed ID: 38521165
[TBL] [Abstract][Full Text] [Related]
30. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.
Pu D; Xu Q; Zhou LY; Zhou YW; Liu JY; Ma XL
Thorac Cancer; 2021 Nov; 12(21):2914-2923. PubMed ID: 34581010
[TBL] [Abstract][Full Text] [Related]
31. Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
Kreinbrink PJ; Li J; Parajuli S; Wise-Draper TM; Choi DL; Tang AL; Takiar V
Oral Oncol; 2021 May; 116():105245. PubMed ID: 33901866
[TBL] [Abstract][Full Text] [Related]
32. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer.
Guo W; Cai S; Zhang F; Shao F; Zhang G; Zhou Y; Zhao L; Tan F; Gao S; He J
Thorac Cancer; 2019 Apr; 10(4):761-768. PubMed ID: 30734516
[TBL] [Abstract][Full Text] [Related]
33. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
34. Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy.
Joseph N; McWilliam A; Kennedy J; Haslett K; Mahil J; Gavarraju A; Mistry H; Van Herk M; Faivre-Finn C; Choudhury A
Radiother Oncol; 2019 Jun; 135():115-119. PubMed ID: 31015156
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma.
Duan H; Zhang X; Wang FX; Cai MY; Ma GW; Yang H; Fu JH; Tan ZH; Meng YQ; Fu XY; Ma QL; Lin P
World J Gastroenterol; 2015 May; 21(18):5591-7. PubMed ID: 25987784
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.
Kwon YS; Han CS; Yu JW; Kim S; Modi P; Davis R; Park JH; Lee P; Ha YS; Kim WJ; Kim IY
Clin Genitourin Cancer; 2016 Feb; 14(1):e1-8. PubMed ID: 26341038
[TBL] [Abstract][Full Text] [Related]
37. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
38. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
[TBL] [Abstract][Full Text] [Related]
39. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.
Reddy AV; Hill CS; Sehgal S; Zheng L; He J; Laheru DA; Jesus-Acosta A; Herman JM; Meyer J; Narang AK
Radiat Oncol J; 2022 Jun; 40(2):111-119. PubMed ID: 35796114
[TBL] [Abstract][Full Text] [Related]
40. Higher aorta dose increased neutrophil-to-lymphocyte ratio resulting in poorer outcomes in stage II-III non-small cell lung cancer.
Li Y; Fan X; Yu Q; Zhai H; Mi J; Lu R; Jiang G; Wu K
Thorac Cancer; 2023 Feb; 14(6):555-562. PubMed ID: 36604971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
